Current landscape of clinical development and approval of advanced therapies
Advanced therapy medicinal products (ATMPs) are innovative therapies that mainly target orphan diseases and high unmet medical needs. The uncertainty about the product's benefit-risk balance at the time of approval, the limitations of nonclinical development, and the complex quality aspects of...
Guardado en:
Autores principales: | Carolina Iglesias-Lopez, Antonia Agustí, Antoni Vallano, Merce Obach |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/43c715acca8f4480a4c1e57dcd181861 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union
por: Carolina Iglesias-Lopez, et al.
Publicado: (2021) -
Investigación y desarrollo de nuevos medicamentos: de la molécula al fármaco
por: Marovac,Jacqueline
Publicado: (2001) -
Induced pluripotent stem cells: advances to applications
por: Timothy J Nelson, et al.
Publicado: (2009) -
Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements
por: Michael L Levy, et al.
Publicado: (2009) -
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau O, et al.
Publicado: (2014)